Labcorp Announces 2023 Third Quarter Results

Company Updates Full-Year Guidance Third quarter revenue grew 6.6% versus last year as the Base Business grew 14.0%.  Results from Continuing Operations for third quarter versus last year: Revenue: $3.06 billion versus $2.87 billion Diluted EPS: $2.11 versus $3.06 Adjusted EPS: $3.38 versus $4.01

Comprehensive NGS Profiling to Enable Detection of ALK Gene Rearrangements and MET Amplifications in Non-Small Cell Lung Cancer

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

White Paper: Tissue Handling and Stewardship Recommendations for OmniSeq INSIGHT® Testing – A Pre Analytical Approach to Comprehensive Genomic Profiling

Download White Paper

Ronald Przygodzki, MD

Dr. Ronald Przygodzki is board certified in anatomic and clinical pathology with sub-specialization in molecular genetic pathology.  He earned his medical degree from the Medical University of Warsaw, as well as residencies in pathology and laboratory medicine at University of Illinois at Chicago and Brown University Rhode Island Hospital, respectively.  Dr.

Molecular Tumor Board: 56 year-old female with Stage IIIC2 endometrial cancer, PD-L1 <1%, MSI-H, TMB-H

Molecular Tumor Board: 48 year-old female with cutaneous melanoma harboring NRAS Q61R mutation

Molecular Tumor Board: 64 year-old female with recurrent breast cancer and PIK3CA mutation

Genetic testing: How iGeniE streamlines result delivery for providers and patients

The landscape of prenatal genetic screening is rapidly evolving, with more conditions, complexity and positive results than ever before. While this information empowers patients, it also creates new challenges for providers. Explaining nuanced genetic concepts is time-consuming, and the concepts can be difficult for patients to grasp in a single appointment. According to a recent scientific study, 88% of patients agree that video explanations make results easier to understand.1